The two forms of CJC-1295 and why the difference matters.
| Attribute | CJC-1295 with DAC Research use only | CJC-1295 without DAC (Mod GRF 1-29) Research use only |
|---|---|---|
| Class / type | Long-acting GHRH analog | Short-acting GHRH analog |
| How it works | Binds pituitary GHRH receptors to stimulate GH synthesis/release; DAC extends half-life, giving sustained (non-pulsatile) GH/IGF-1 elevation. | Binds pituitary GHRH receptors to trigger a short GH pulse mimicking natural release; often paired with a GHRP (e.g., ipamorelin). |
| Known / used for | No approved use; off-label/research for body composition, recovery, anti-aging. | No approved use; off-label/research for GH optimization, body composition, sleep, recovery. |
| Positives | Phase 1 data: single doses raised GH 2-10x and IGF-1 1.5-3x for 9-11 days; convenient weekly dosing; reported sleep/recovery/skin benefits. | Pulsatile release closer to physiologic patterns; short duration seen as preserving feedback; user-reported recovery/sleep/skin benefits. |
| Negatives & risks | No long-term human safety data; sustained GH/IGF-1 elevation risks edema, insulin resistance, joint pain, carpal-tunnel symptoms; purity unverified. | Requires frequent injections (often 1-3x/day); no long-term human data; possible fluid retention, tingling, injection-site reactions; purity concerns. |
| Legal status (Jul 2026) | NOT FDA-approved. Added to Category 2 (2023), removed (2024); pending PCAC review. Research-use-only; WADA-banned. | NOT FDA-approved. Same regulatory path as CJC-1295 (Cat 2 2023, removed 2024, pending PCAC). Research-use-only; WADA-banned. |